TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02705573
Drug: Mannitol
Normalized name: Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the study, mannitol 20% with a dose of 1g / kg / BW (5 ml / kg / BW) will be compared to placebo with NaCl 0.9% in the dose of 5 ml / kg / BW. The study medication will be administered immediately before organ reperfusion. The follow-up of the study is 24 hours.
Study: NCT02019069
Drug: liposomal cytarabine-daunorubicin CPX-351
Normalized name: cytarabine / daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03639389
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinal anesthesia with a combination of bupivacaine and fentanyl or sufentanil
Study: NCT01877564
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02991196
Drug: DS-8273a + nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered \[90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions\] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
Study: NCT02959879
Drug: FOLFOX neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
Study: NCT02959879
Drug: FOLFIRINOX neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
Study: NCT03415867
Drug: Glasdegib
Normalized name: Glasdegib
DrugBank: Glasdegib (DB11978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A dose escalation/de-escalation design will be applied in successive patient cohorts until identification of MTD (dose range: 25-200 mg OD).
Study: NCT02182596
Drug: Mylotarg
Normalized name: Mylotarg
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose level study
Study: NCT00042835
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00042835
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00042835
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00042835
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00042835
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00042835
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02827097
Drug: denogan and rectus sheath block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of denogan and rectus sheath block with 0.375% ropivacaine
Study: NCT04146805
Drug: BLD-0409
Normalized name: BLD-0409
DrugBank: Cudetaxestat (DB18203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each cohort in both study parts, 8 subjects will be randomized in a 6:2 ratio to active (BLD-0409) : control (matched placebo). Study drug will be administered orally once a day, with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
Study: NCT04425031
Drug: Low oxygenation target
Normalized name: low-density polyethylene
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
Study: NCT04425031
Drug: High oxygenation target
Normalized name: high-density polyethylene
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
Study: NCT00820885
Drug: teduglutide
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
Study: NCT00820885
Drug: teduglutide
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
Study: NCT00820885
Drug: tedguglutide
Normalized name: Teduglutide
DrugBank: Teduglutide (DB08900)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
Study: NCT02906059
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01341951
Drug: Granulocyte colony stimulating factor
Normalized name: Granulocyte colony stimulating factor
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 I.U twice daily for 5 days
Study: NCT03701451
Drug: Demethylated drug decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Induced treatment by demethylating drug decitabine 7mg/m2 d1-5 and cisplatin 80mg/m2 d1 for 3 cycles to regionally advanced nasopharyngeal carcinoma followed by concurrent chemoradiotherapy with cisplatin 80mg/m2 d1 for 3 cycles.
Study: NCT00623077
Drug: busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (\>4 yrs of age) or 13.2 mg/kg IV (\< 4 years of age),every 6 hours on Days -8 through -6.
Study: NCT00623077
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m\^2/day intravenous (IV) over 1 hour for 5 days.
Study: NCT00623077
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day intravenous (IV) over 1 hour on for 5 days.
Study: NCT00623077
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m\^2 intravenous (IV) over 30 min on Days -5 through -4.
Study: NCT00623077
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m\^2 intravenously (IV) over 2 hrs on Days -3 through -2.
Study: NCT03421119
Drug: Liraglutide 6 MG/ML Pen Injector
Normalized name: liraglutide 6 MG/ML Pen Injector
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector.
Study: NCT04607733
Drug: Mirikizumab Prefilled Syringe
Normalized name: mirikizumab Prefilled Syringe
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC by prefilled syringe
Study: NCT04607733
Drug: Mirikizumab Autoinjector
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC by autoinjector
Study: NCT00623077
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m\^2/day divided in every 6 hrs dosing for 5 days.
Study: NCT00577993
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1= 25 mg/m\^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m\^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
Study: NCT00577993
Drug: Novantrone
Normalized name: Novantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1 = 10 mg/m\^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m\^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m\^2 IV over 15 min. Day 2 of 3rd Sequence.
Study: NCT00577993
Drug: Decadron
Normalized name: Decadron
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
Study: NCT00171145
Drug: Darifenacin
Normalized name: Darifenacin
DrugBank: Darifenacin (DB00496)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Darifenacin 15 mg tablets once daily
Study: NCT00577993
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Group 1 = 375 mg/m\^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m\^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m\^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m\^2 IV Days 1 through 8 of 3rd Sequence.
Study: NCT00577993
Drug: Interferon
Normalized name: Interferon
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group 1 = After Completion of Fludarabine, Novantrone, \& Rituximab, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine \& Novantrone, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m\^2 SQ Days 1 through 14 Each Month for 1 year.
Study: NCT00577993
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: .7 mg/m\^2 IV Days 2 \& 3 of 1st Sequence; 1.4 mg/m\^2 IV Day 2 of 3rd Sequence.
Study: NCT00577993
Drug: Bleomycin
Normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 unit/m\^2 IV Days 2 \& 3 of 1st Sequence.
Study: NCT00577993
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg/m\^2 IV Days 1 through 4 of 2nd Sequence.
Study: NCT02581527
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin 150mg (Control arm); Rifampicin 1200mg (Regimen 1); Rifampicin 1800mg (Regimen 2)
Study: NCT02581527
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid 75mg - all arms
Study: NCT02581527
Drug: Ethambutol
Normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethambutol 275mg - all arms
Study: NCT02581527
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrazinamide 400mg - all arms
Study: NCT01663662
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03421119
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study.
Study: NCT02501473
Drug: G100
Normalized name: G100
DrugBank: G100 (DB17244)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
Study: NCT02501473
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PD-1 Inhibitor
Study: NCT02501473
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (anti-CD20 antibody)
Study: NCT00577993
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 IV Days 1 through 4 of 2nd Sequence
Study: NCT00577993
Drug: Ara-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.5 gm/m\^2 IV Day 5 of 2nd Sequence.
Study: NCT00577993
Drug: Methyl-Prednisolone
Normalized name: Prednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg IV Days 1 through 5 of 2nd Sequence.
Study: NCT00577993
Drug: Procarbazine
Normalized name: Procarbazine
DrugBank: Procarbazine (DB01168)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m\^2 PO Days 2 through 11 of 3rd Sequence.
Study: NCT00577993
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg PO Days 1 through 5 of 3rd Sequence.
Study: NCT03069976
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flagyl x 14 days.
Study: NCT00548431
Drug: 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard dose 25 mg/m\^2/day. Can be increased up to 75 mg/m\^2/day if the myelosuppression is acceptable (ANC\>0.5 T-count \>50)
Study: NCT03357380
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
Study: NCT03103594
Drug: DMSO
Normalized name: DMSO
DrugBank: Dimethyl sulfoxide (DB01093)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DMSO will be instilled intravesically.
Study: NCT03103594
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Botox will be instilled intravesically with DMSO.
Study: NCT01131091
Drug: SK-0403
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SK-0403 400 mg
Study: NCT00854126
Drug: GDC-0980
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escalating repeating dose
Study: NCT02508805
Drug: Voltaren
Normalized name: Voltaren
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01978873
Drug: Cabazitaxel + Androgen deprivation therapy
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
Study: NCT01159873
Drug: CEP-37251
Normalized name: CEP-9722
DrugBank: CEP-9722 (DB14882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
Study: NCT02117830
Drug: Androxal 25 mg capsules
Normalized name: testosterone 20.25 MG/ACTUAT [Androgel]
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02117830
Drug: Moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04039230
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib belongs to a group of drugs called PARP inhibitors. PARP is a protein that is involved with repairing damaged DNA (the genetic material of cells). Talazoparib is believed to work by inhibiting (stopping) the PARP proteins from working in the cancer cells so that the cancer cannot fix its damaged DNA.
Study: NCT04039230
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan is believed to work by binding the antibody portion of the drug to the tumor(s) while the anticancer drug portion works to prevent the cancer cells from growing/spreading.
Study: NCT01372930
Drug: Etanercept
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
Study: NCT01372930
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: saline 1ml(subcutaneous injection) at 2h and 72h after PCI
Study: NCT02508805
Drug: Sirdalud
DrugBank: Tizanidine (DB00697)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02217566
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive abiraterone acetate 1000 mg (4\*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
Study: NCT04837664
Drug: Curcumin
Normalized name: Curcumin
DrugBank: Curcumin (DB11672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin was bought from Sigma®, USA, and its solution was freshly prepared by mixing curcumin powder with phosphate-buffered saline.
Study: NCT04837664
Drug: Rose Bengal
Normalized name: Rose bengal
DrugBank: Rose bengal (DB11182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rose bengal was bought from Sigma®, USA, and its solution was freshly prepared by mixing rose bengal powder with phosphate-buffered saline.
Study: NCT04837664
Drug: Nystatin
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rinsing with topical nystatin (100,000 UI/mL) suspension for 60 seconds
Study: NCT02217566
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
Study: NCT01476501
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
Study: NCT00004978
Drug: Recombinant interleukin-2 (rIL-2)
Normalized name: Recombinant human interleukin-2
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
Study: NCT02414750
Drug: Vemurafenib plus cobimetinib
Normalized name: Vemurafenib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Molecular targeted therapy for BRAF mutated advanced melanoma patients
Study: NCT03500627
Drug: OP-101
Normalized name: OP-101
DrugBank: Acetylcysteine zidrimer (DB16496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Injection of OP-101 in healthy volunteers.
Study: NCT00004814
Drug: copolymer 1
Normalized name: glatiramer (copolymer 1)
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04417348
Drug: Retinoic acid
Normalized name: Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To evaluate the role of Opsin receptors in melasma. The patients were treated with 0.05% Retinoic Acid, a regular therapy to treatment melasma, a ligand of Opsin receptors. Also, Uv-Visible light filter treatment as a posible opsin receptor blocker
Study: NCT04160091
Drug: FX006
Normalized name: Triamcinolone Acetonide Extended-Release
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intra-articular injection
Study: NCT01138553
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg capsules daily for 5-28 days
Study: NCT01659775
Drug: Sancuso patch
Normalized name: Sancuso
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy.
Study: NCT02296242
Drug: BVD-523
Normalized name: BVdU
DrugBank: Brivudine (DB03312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
Study: NCT04393610
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive lidocaine 3 mg/kg total of 40 ml (control group).
Study: NCT03131050
Drug: Scopolamine
Normalized name: Scopolamine
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;
Study: NCT03131050
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
Study: NCT03131050
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
Study: NCT00374790
Drug: Ferrous sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02536040
Drug: 38% diammine silver fluoride
DrugBank: Silver nitrate (DB11080)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment of cavity with study agent
Study: NCT04393610
Drug: Magnesium Sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.
Study: NCT01196390
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV